• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

针对阿尔茨海默病:新型茚满酮杂合体含有 AP2238 的药效团片段。

Targeting Alzheimer's disease: Novel indanone hybrids bearing a pharmacophoric fragment of AP2238.

机构信息

Department of Pharmaceutical Sciences, University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy.

出版信息

Bioorg Med Chem. 2010 Mar 1;18(5):1749-60. doi: 10.1016/j.bmc.2010.01.071. Epub 2010 Feb 4.

DOI:10.1016/j.bmc.2010.01.071
PMID:20171894
Abstract

We report on a series of hybrid compounds structurally derived from donepezil and AP2238. This study was aimed at improving the activities of the reference compounds, donepezil and AP2238, and at broadening the range of activities of new derivatives as, due to the multifactorial nature of AD, molecules that modulate the activity of a single protein target are unable to significantly modify the progression of the disease. In particular, the indanone core from donepezil was linked to the phenyl-N-methylbenzylamino moiety from AP2238, through a double bond that was kept to evaluate the role of a lower flexibility in the biological activities. Moreover, SAR studies were performed to evaluate the role of different substituents in position 5 or 6 of the indanone ring in the interaction with the PAS, introducing also alkyl chains of different lengths carrying different amines at one end. Derivatives 21 and 22 proved to be the most active within the series and their potencies against AChE were in the same order of magnitude of the reference compounds. Compounds 15, 21-22, with a 5-carbon alkyl chain bearing an amino moiety at one end, better contacting the PAS, remarkably improved the inhibition of AChE-induced Abeta aggregation with respect to the reference compounds. They also showed activity against self-aggregation of Abeta(42) peptide, the most amyloidogenic form of amyloid produced in AD brains, while the reference compounds resulted completely ineffective.

摘要

我们报告了一系列结构上源自多奈哌齐和 AP2238 的杂合化合物。这项研究旨在提高参考化合物多奈哌齐和 AP2238 的活性,并拓宽新衍生物的活性范围,因为由于 AD 的多因素性质,调节单一蛋白靶标活性的分子无法显著改变疾病的进展。特别是,通过双键将多奈哌齐的茚满酮核心与 AP2238 的苯-N-甲基苄基氨基部分连接起来,保持这种较低的灵活性来评估其在生物活性中的作用。此外,还进行了 SAR 研究,以评估茚满酮环 5 或 6 位上不同取代基在与 PAS 相互作用中的作用,同时在一端引入具有不同长度烷基链的不同胺。衍生物 21 和 22 在该系列中表现出最强的活性,它们对 AChE 的活性与参考化合物相当。化合物 15、21-22 带有一个 5 个碳原子的烷基链,一端带有一个氨基部分,更好地与 PAS 接触,显著提高了对 AChE 诱导的 Abeta 聚集的抑制作用,与参考化合物相比。它们还显示出对 Abeta(42)肽自聚集的活性,Abeta(42)肽是 AD 大脑中产生的最具淀粉样的淀粉样蛋白形式,而参考化合物则完全无效。

相似文献

1
Targeting Alzheimer's disease: Novel indanone hybrids bearing a pharmacophoric fragment of AP2238.针对阿尔茨海默病:新型茚满酮杂合体含有 AP2238 的药效团片段。
Bioorg Med Chem. 2010 Mar 1;18(5):1749-60. doi: 10.1016/j.bmc.2010.01.071. Epub 2010 Feb 4.
2
Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abeta1-42 aggregation for Alzheimer's disease therapeutics.用于阿尔茨海默病治疗的具有双重抑制乙酰胆碱酯酶和β淀粉样蛋白1-42聚集活性的新型哌啶衍生物的合成、体外测定及分子模拟
Bioorg Med Chem. 2007 Oct 15;15(20):6596-607. doi: 10.1016/j.bmc.2007.07.003. Epub 2007 Jul 25.
3
Extensive SAR and computational studies of 3-{4-[(benzylmethylamino)methyl]phenyl}-6,7-dimethoxy-2H-2-chromenone (AP2238) derivatives.3-{4-[(苄基甲基氨基)甲基]苯基}-6,7-二甲氧基-2H-2-色原酮(AP2238)衍生物的广泛构效关系及计算研究
J Med Chem. 2007 Aug 23;50(17):4250-4. doi: 10.1021/jm070100g. Epub 2007 Jul 26.
4
Multitarget Strategy to Address Alzheimer's Disease: Design, Synthesis, Biological Evaluation, and Computational Studies of Coumarin-Based Derivatives.应对阿尔茨海默病的多靶点策略:基于香豆素的衍生物的设计、合成、生物学评价及计算研究
ChemMedChem. 2016 Jun 20;11(12):1296-308. doi: 10.1002/cmdc.201500392. Epub 2015 Oct 28.
5
3-(4-[[Benzyl(methyl)amino]methyl]phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation: a dual function lead for Alzheimer's disease therapy.3-(4-[[苄基(甲基)氨基]甲基]苯基)-6,7-二甲氧基-2H-2-色原酮(AP2238)可抑制乙酰胆碱酯酶和乙酰胆碱酯酶诱导的β-淀粉样蛋白聚集:阿尔茨海默病治疗的双重作用先导物
J Med Chem. 2003 Jun 5;46(12):2279-82. doi: 10.1021/jm0340602.
6
Novel donepezil-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation.新型基于多奈哌齐的乙酰胆碱酯酶和丁酰胆碱酯酶抑制剂以及乙酰胆碱酯酶诱导的β-淀粉样蛋白聚集。
J Med Chem. 2008 Jun 26;51(12):3588-98. doi: 10.1021/jm8001313. Epub 2008 Jun 3.
7
Tacrine-based dual binding site acetylcholinesterase inhibitors as potential disease-modifying anti-Alzheimer drug candidates.基于他克林的双结合位点乙酰胆碱酯酶抑制剂作为有潜力的治疗阿尔茨海默病的药物候选物。
Chem Biol Interact. 2010 Sep 6;187(1-3):411-5. doi: 10.1016/j.cbi.2010.02.013. Epub 2010 Feb 16.
8
Benzophenone-based derivatives: a novel series of potent and selective dual inhibitors of acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation.基于二苯甲酮的衍生物:一种新型的乙酰胆碱酯酶和乙酰胆碱酯酶诱导的β-淀粉样蛋白聚集的双重抑制剂,具有高效和选择性。
Eur J Med Chem. 2011 May;46(5):1682-93. doi: 10.1016/j.ejmech.2011.02.019. Epub 2011 Feb 22.
9
Donepezil-tacrine hybrid related derivatives as new dual binding site inhibitors of AChE.多奈哌齐-他克林杂合相关衍生物作为乙酰胆碱酯酶的新型双结合位点抑制剂
Bioorg Med Chem. 2005 Dec 15;13(24):6588-97. doi: 10.1016/j.bmc.2005.09.029. Epub 2005 Oct 17.
10
Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.多奈哌齐和 N-[(5-(苄氧基)-1-甲基-1H-吲哚-2-基)甲基]-N-甲基丙-2-炔-1-胺杂合体的合成、生物评价和分子模拟作为治疗阿尔茨海默病的新型多效胆碱酯酶/单胺氧化酶抑制剂。
J Med Chem. 2011 Dec 22;54(24):8251-70. doi: 10.1021/jm200853t. Epub 2011 Nov 15.

引用本文的文献

1
Design strategies, structural insights, and biological potential of amyloid-beta inhibitors in Alzheimer's disease.阿尔茨海默病中β-淀粉样蛋白抑制剂的设计策略、结构见解及生物学潜力
Mol Divers. 2025 Jul 3. doi: 10.1007/s11030-025-11278-4.
2
Hybrid/Chimera Drugs - Part 1 - Drug Hybrids Affecting Diseases of the Central Nervous System.杂交/嵌合药物 - 第1部分 - 影响中枢神经系统疾病的药物杂交体
Curr Med Chem. 2025;32(23):4603-4656. doi: 10.2174/0109298673305662240702071354.
3
Synthetic and Natural Bioactive Molecules in Balancing the Crosstalk among Common Signaling Pathways in Alzheimer's Disease: Understanding the Neurotoxic Mechanisms for Therapeutic Intervention.
合成与天然生物活性分子在阿尔茨海默病常见信号通路串扰平衡中的作用:理解治疗干预的神经毒性机制
ACS Omega. 2023 Oct 20;8(43):39964-39983. doi: 10.1021/acsomega.3c05662. eCollection 2023 Oct 31.
4
Investigation on Novel 2-Benzylideneindan-1-One-Based Photoswitches with AChE and MAO-B Dual Inhibitory Activity.新型 2-亚苄基茚满-1-酮类化合物的设计、合成及对 AChE 和 MAO-B 的双重抑制活性研究
Molecules. 2023 Aug 3;28(15):5857. doi: 10.3390/molecules28155857.
5
Novel Morpholine-Bearing Quinoline Derivatives as Potential Cholinesterase Inhibitors: The Influence of Amine, Carbon Linkers and Phenylamino Groups.新型吗啉基喹啉衍生物作为潜在的胆碱酯酶抑制剂:胺、碳连接基团和苯氨基的影响。
Int J Mol Sci. 2022 Sep 23;23(19):11231. doi: 10.3390/ijms231911231.
6
The State of The Art on Acetylcholinesterase Inhibitors in the Treatment of Alzheimer's Disease.乙酰胆碱酯酶抑制剂治疗阿尔茨海默病的研究现状
J Cent Nerv Syst Dis. 2021 Jul 7;13:11795735211029113. doi: 10.1177/11795735211029113. eCollection 2021.
7
Novel Donepezil-Arylsulfonamide Hybrids as Multitarget-Directed Ligands for Potential Treatment of Alzheimer's Disease.新型多奈哌齐-芳基磺酰胺杂合体作为潜在阿尔茨海默病治疗的多靶点导向配体。
Molecules. 2021 Mar 16;26(6):1658. doi: 10.3390/molecules26061658.
8
Chalcone and its analogs: Therapeutic and diagnostic applications in Alzheimer's disease.查尔酮及其类似物:阿尔茨海默病治疗和诊断应用。
Bioorg Chem. 2021 Mar;108:104681. doi: 10.1016/j.bioorg.2021.104681. Epub 2021 Jan 29.
9
Multi-Target Drug Candidates for Multifactorial Alzheimer's Disease: AChE and NMDAR as Molecular Targets.多靶点药物候选物治疗多因素阿尔茨海默病:AChE 和 NMDAR 作为分子靶点。
Mol Neurobiol. 2021 Jan;58(1):281-303. doi: 10.1007/s12035-020-02116-9. Epub 2020 Sep 15.
10
Alzheimer's Disease Pharmacotherapy in Relation to Cholinergic System Involvement.阿尔茨海默病药物治疗与胆碱能系统参与的关系。
Biomolecules. 2019 Dec 26;10(1):40. doi: 10.3390/biom10010040.